

We are prepared to tackle a variant like Omicron. From studies of the Beta & Delta variants, we established an approach to develop and produce variant versions of our vaccine in ~100 days, if needed, and subject to regulatory approval.
— Albert Bourla (@AlbertBourla) November 30, 2021
If authorized, we’re confident our oral antiviral therapy can help reduce the severity of illness, and we now anticipate we can deliver 80M treatment courses, up from our original estimate of 50M. Going forward, we will continue to follow the science in our ongoing fight.
— Albert Bourla (@AlbertBourla) November 30, 2021